)
)
)
Neuropathix, Inc. is a drug discovery company with globally patented anti-inflammatory technology. Our lead compound KLS-13019, is a first-in-class, non-opioid, non-NSAID that has been validated through IND enabling studies to prevent and reverse chemotherapy induced peripheral neuropathy (CIPN). Preclinical animal studies to date indicate KLS-13019’s ground-breaking potential in treating neuro-inflammation, neuropathic pain, and opioid use disorder. In addition to our drug’s ability to reverse neuropathic pain, animal studies have shown KLS-13019’s ability to reduce morphine reward seeking (addiction), and withdrawal symptoms (aggression and anxiety) caused by the use of naloxone after chronic morphine dosing.
Year Founded
2010 (subsidiary - Kannalife Sciences, Inc.) 2013 (parent company - Neuropathix, Inc.)
Next catalyst (value inflection) update
Completion of Animal Tox (28 day dog and 28 day rat) - est. completion December 2025 Manufacturing GMP batch material for FIH clinical trials - est. completion September 2025 Filing an IND with the FDA Q2 2026
Expected time of next catalyst update
See above response to Question 7.
City
Doylestown
Country
United States
Company CEO or top company official
Dean Petkanas
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
KLS-13019 (IND enabled)
Number of Unlicensed Products
Two
Therapeutic Area
Pain Management
Website
https://neuropathix.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
